Literature DB >> 16219800

Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis.

Nichola Cooper1, Kanchan Rao, Kimberly Gilmour, Lema Hadad, Stuart Adams, Cathy Cale, Graham Davies, David Webb, Paul Veys, Persis Amrolia.   

Abstract

Allogeneic stem cell transplantation (SCT) is curative for hemophagocytic lymphohistiocytosis (HLH). However, patients frequently have significant morbidity before transplantation and there is high transplant-related mortality (TRM). Because first-degree HLH is caused by immune dysregulation, a reduced-intensity conditioned (RIC) regimen might be sufficient for cure while decreasing the TRM. Twelve patients with HLH underwent RIC SCT from a matched family/unrelated or haploidentical donor. Eleven were conditioned with fludarabine/melphalan with additional busulphan for haploidentical grafts. One received fludarabine and 2-Gy total body irradiation (TBI). All patients showed engraftment at a median of 14 days. Nine of 12 (75%) are alive and in complete remission (CR) a median of 30 months (range, 9-73 months) after SCT. Two patients died from pneumonitis and one from hepatic rupture. Four patients developed acute graft-versus-host disease (GVHD) and 3 have chronic GVHD. Three of 9 survivors have mixed chimerism but remain free of disease. In summary, RIC compares favorably to conventional SCT with long-term disease control in surviving patients despite a significant incidence of mixed chimerism.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16219800     DOI: 10.1182/blood-2005-05-1819

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease.

Authors:  Claire Booth; Kimberly C Gilmour; Paul Veys; Andrew R Gennery; Mary A Slatter; Helen Chapel; Paul T Heath; Colin G Steward; Owen Smith; Anna O'Meara; Hilary Kerrigan; Nizar Mahlaoui; Marina Cavazzana-Calvo; Alain Fischer; Despina Moshous; Stephane Blanche; Jana Pachlopnik Schmid; Jana Pachlopnick-Schmid; Sylvain Latour; Genevieve de Saint-Basile; Michael Albert; Gundula Notheis; Nikolaus Rieber; Brigitte Strahm; Henrike Ritterbusch; Arjan Lankester; Nico G Hartwig; Isabelle Meyts; Alessandro Plebani; Annarosa Soresina; Andrea Finocchi; Claudio Pignata; Emilia Cirillo; Sonia Bonanomi; Christina Peters; Krzysztof Kalwak; Srdjan Pasic; Petr Sedlacek; Janez Jazbec; Hirokazu Kanegane; Kim E Nichols; I Celine Hanson; Neena Kapoor; Elie Haddad; Morton Cowan; Sharon Choo; Joanne Smart; Peter D Arkwright; Hubert B Gaspar
Journal:  Blood       Date:  2010-10-06       Impact factor: 22.113

2.  Allogeneic hematopoietic stem-cell transplantation for adult and adolescent hemophagocytic lymphohistiocytosis: a single center analysis.

Authors:  Li Fu; Jingshi Wang; Na Wei; Lin Wu; Yini Wang; Wenqiu Huang; Jia Zhang; Jinli Liu; Zhao Wang
Journal:  Int J Hematol       Date:  2016-07-18       Impact factor: 2.490

3.  Alternative-Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Nonmalignant Disorders.

Authors:  Orly R Klein; Allen R Chen; Christopher Gamper; David Loeb; Elias Zambidis; Nicolas Llosa; Jeffrey Huo; Amy E Dezern; Diana Steppan; Nancy Robey; Mary Jo Holuba; Kenneth R Cooke; Heather J Symons
Journal:  Biol Blood Marrow Transplant       Date:  2016-02-06       Impact factor: 5.742

Review 4.  Hemophagocytic Syndrome and Critical Illness: New Insights into Diagnosis and Management.

Authors:  Zuzana Tothova; Nancy Berliner
Journal:  J Intensive Care Med       Date:  2014-01-08       Impact factor: 3.510

Review 5.  Transplantation in rare lymphoproliferative and histiocytic disorders.

Authors:  Alexis Cruz-Chacon; John Mathews; Ernesto Ayala
Journal:  Cancer Control       Date:  2014-10       Impact factor: 3.302

Review 6.  Reduced-intensity conditioning haematopoietic cell transplantation for haemophagocytic lymphohistiocytosis: an important step forward.

Authors:  Rebecca A Marsh; Michael B Jordan; Alexandra H Filipovich
Journal:  Br J Haematol       Date:  2011-06-28       Impact factor: 6.998

7.  Hematopoietic stem cell transplantation in children with Griscelli syndrome type 2: a single-center report on 35 patients.

Authors:  M Al-Mofareh; M Ayas; A Al-Seraihy; K Siddiqui; A Al-Jefri; I Ghemlas; H Alsaedi; H El-Solh; S Al-Sweedan; B Al-Saud; H Al-Mousa; H Al-Dhekri; R Arnaout; R Mohammed; S Al-Muhsen; A Al-Ahmari
Journal:  Bone Marrow Transplant       Date:  2020-04-14       Impact factor: 5.483

8.  Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008.

Authors:  J I Cohen; H Kimura; S Nakamura; Y-H Ko; E S Jaffe
Journal:  Ann Oncol       Date:  2009-06-10       Impact factor: 32.976

9.  A novel reduced-intensity conditioning regimen for unrelated umbilical cord blood transplantation in children with nonmalignant diseases.

Authors:  Suhag H Parikh; Adam Mendizabal; Cara L Benjamin; Krishna V Komanduri; Jeyaraj Antony; Aleksandra Petrovic; Gregory Hale; Timothy A Driscoll; Paul L Martin; Kristin M Page; Ketti Flickinger; Jerelyn Moffet; Donna Niedzwiecki; Joanne Kurtzberg; Paul Szabolcs
Journal:  Biol Blood Marrow Transplant       Date:  2013-12-01       Impact factor: 5.742

10.  Blood and Marrow Transplant Clinical Trials Network: progress since the State of the Science Symposium 2007.

Authors:  James L M Ferrara
Journal:  Biol Blood Marrow Transplant       Date:  2013-11-12       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.